These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 7055531)

  • 1. Comparison of antithrombin III assays using biological and chromogenic substrates.
    Philo RD; Gaffney PJ
    Br J Haematol; 1982 Jan; 50(1):147-56. PubMed ID: 7055531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic peptide substrates in hemostatic testing.
    Fareed J; Messmore HL; Walenga JM; Bermes EW
    Crit Rev Clin Lab Sci; 1983; 19(2):71-134. PubMed ID: 6373139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reliability of amidolytic assays for progressive antithrombin and heparin cofactor activities on capillary blood.
    Hurlet-Birk Jensen A; Maes E; Gillet C; Legrand-Monsieur A
    Thromb Haemost; 1980 Jun; 43(2):104-7. PubMed ID: 7455966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurement of antithrombin III in normal and pathologic states using chromogenic substrate S-2238. Comparison with immunoelectrophoretic and factor Xa inhibition assays.
    Goodnight SH; Schaeffer JL; Sheth K
    Am J Clin Pathol; 1980 May; 73(5):639-47. PubMed ID: 7377131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prothrombin fragment 1 + 2, thrombin-antithrombin III-complexes and fibrinopeptide A in spontaneously clotting whole blood in vitro. Effects of heparin addition and antithrombin III deficiency.
    Herren T; Straub PW; Haeberli A
    Thromb Haemost; 1994 Jan; 71(1):49-53. PubMed ID: 8165646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antithrombin-III assay without influence of heparin cofactor II.
    Enomoto M; Tanimizu I; Sakuragawa N
    Thromb Res; 1990 Mar; 57(5):729-36. PubMed ID: 2339367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombin-based antithrombin assays show overestimation of antithrombin III activity in patients on heparin therapy due to heparin cofactor II influence.
    Bohner J; von Pape KW; Blaurock M
    Thromb Haemost; 1994 Mar; 71(3):280-3. PubMed ID: 8029789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Migration inhibition factor and the blood clotting system: effects of defibrination, heparin and thrombin.
    Mäkinen T; Tötterman TH; Gordin A; Weber TH
    Clin Exp Immunol; 1977 Jul; 29(1):181-6. PubMed ID: 330064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A simple method to measure dermatan sulfate at sub-microgram concentrations in plasma.
    Dupouy D; Sié P; Dol F; Boneu B
    Thromb Haemost; 1988 Oct; 60(2):236-9. PubMed ID: 3217919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heparin cofactor activity measured with an amidolytic method.
    Odegard OR; Lie M; Abildgaard U
    Thromb Res; 1975 Apr; 6(4):287-94. PubMed ID: 49087
    [No Abstract]   [Full Text] [Related]  

  • 11. A simple amidolytic method for the determination of functional active antithrombin III.
    Abildaard U; Lie M; Odegård OR
    Scand J Clin Lab Invest; 1976 Jan; 36(1):109-12. PubMed ID: 815998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antifactor Xa activity measured with amidolytic methods.
    Odegård OR; Lie M; Abildgaard U
    Haemostasis; 1976; 5(5):265-75. PubMed ID: 1017722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring of heparin treatment. Comparison of thrombin time, activated partial thromboplastin time, and plasma heparin concentration, and analysis of the behavior of antithrombin III.
    Bounameaux H; Marbet GA; Lämmle B; Eichlisberger R; Duckert F
    Am J Clin Pathol; 1980 Jul; 74(1):68-73. PubMed ID: 7395817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemodialysis and heparin. Alternative methods of measuring heparin and of detecting activation of coagulation.
    Ireland HA; Boisclair MD; Lane DA; Thompson E; Curtis JR
    Clin Nephrol; 1991 Jan; 35(1):26-33. PubMed ID: 1826095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional assay of plasma antithrombin using polyethylene glycol (PEG) defibrinated plasma.
    Li A; Taylor FB; Chang AK; Peer GT; Dong F; Hinshaw LB
    Thromb Res; 1995 Aug; 79(4):395-403. PubMed ID: 7482443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of thrombin by antithrombin III and heparin cofactor II in vivo.
    Liu L; Dewar L; Song Y; Kulczycky M; Blajchman MA; Fenton JW; Andrew M; Delorme M; Ginsberg J; Preissner KT
    Thromb Haemost; 1995 Mar; 73(3):405-12. PubMed ID: 7545318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of an amidolytic heparin cofactor assay method.
    Odegård OR
    Thromb Res; 1975 Aug; 7(2):351-60. PubMed ID: 51519
    [No Abstract]   [Full Text] [Related]  

  • 18. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.
    Weitz JI; Hudoba M; Massel D; Maraganore J; Hirsh J
    J Clin Invest; 1990 Aug; 86(2):385-91. PubMed ID: 2384594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On the mechanism of coagulation inhibition on surfaces with end point immobilized heparin.
    Elgue G; Blombäck M; Olsson P; Riesenfeld J
    Thromb Haemost; 1993 Aug; 70(2):289-93. PubMed ID: 8236137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methods for semi micro or automated determination of thrombin, antithrombin, and heparin cofactor using he substrate, H-D-Phe-Pip-Arg-p-nitroanilide-2HCl.
    Scully MF; Kakkar VV
    Clin Chim Acta; 1977 Sep; 79(3):595-602. PubMed ID: 70286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.